Medicine
Ozempic 4.02 mg/3 mL injection
Ozempic 4.02 mg/3 mL injection is a prescription medicine containing Semaglutide for subcutaneous use, marketed by Novo Nordisk Pharmaceutical Industries, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Storage as on the product label
Key facts
- Active ingredient (INN)
- Semaglutide
- Brand
- Ozempic
- Strength
- 4.02 mg/3 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 1 syringe of 3 mL
- Marketing authorisation holder
- Novo Nordisk Pharmaceutical Industries
- Manufacturers
- Novo Nordisk Pharmaceutical IndustriesA-S Medication Solutions
- Origin register
- US FDA, United States
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A10BJ06 Semaglutide
- HS code (indicative)
- 3004.39Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 30 September 2020
- Identifiers
- RxCUI 2398841, 2398842DailyMed set ID 979e4df4-0597-48ea-b51c-0f699fa6d166NDC 50090-5949, 0169-4130Application NDA209637
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 syringe, plastic in 1 carton / 3 mL in 1 syringe, plastic | 0169-4130-13 | Novo Nordisk Pharmaceutical Industries | 3 January 2021 |
| 1 syringe, plastic in 1 carton / 3 mL in 1 syringe, plastic | 50090-5949-0 | A-S Medication Solutions | 1 April 2022 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Semaglutide
Clinical summary
Semaglutide is a GLP-1 receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, among other approved uses. MedsAcross supplies Semaglutide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about SemaglutideFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- OZEMPIC prescribing information (Novo Nordisk Pharmaceutical Industries) · U.S. National Library of Medicine, DailyMed
- Kayshild: European public assessment report (EPAR) · European Medicines Agency
- Ozempic: European public assessment report (EPAR) · European Medicines Agency
Need Ozempic 4.02 mg/3 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.